drugset

drugset / Trial / NCT04318600

Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis

NCT04318600 ↗

Phase 1 Completed 16 enrolled Yan'an Affiliated Hospital of Kunming Medical University The First People's Hospital of Yunnan · collab

Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study would further evaluate the safety and efficacy of human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis (LN).

Timeline

Start: 2014-01-01
Primary completion: 2017-03-01
Completion: 2019-01-01

Publications

Naeem A, Gupta N, Naeem U, Khan MJ, Elrayess MA, Cui W, Albanese C. A comparison of isolation and culture protocols for human amniotic mesenchymal stem cells. Cell Cycle. 2022 Aug;21(15):1543-1556. doi: 10.1080/15384101.2022.2060641. Epub 2022 Apr 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	human amniotic mesenchymal stem cell	Cell therapy	1e+06 cells/kg	Intravenous

Indications